# Maintaining or Stopping Immunosuppressive Therapy in Patients With ANCA Vasculitis and End-stage Renal Disease

Study · id `cardio:ct-nct03323476` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03323476](<https://clinicaltrials.gov/study/NCT03323476>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03323476

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 136 participants.

## Technical summary

Registry record NCT03323476. Randomized; no masking; primary purpose treatment. Start 2018-02-02 (actual); primary completion 2028-03 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 136 participants (planned count; ClinicalTrials.gov record NCT03323476, source copy `cardio:ctgov-nct03323476-2026-03-20`, retrieved 2026-10-26)
- Started: 2018-02-02 (actual) (ClinicalTrials.gov record NCT03323476, source copy `cardio:ctgov-nct03323476-2026-03-20`, retrieved 2026-10-26)
- Primary completion: 2028-03 (anticipated) (ClinicalTrials.gov record NCT03323476, source copy `cardio:ctgov-nct03323476-2026-03-20`, retrieved 2026-10-26)
- Completion: 2031-03 (anticipated) (ClinicalTrials.gov record NCT03323476, source copy `cardio:ctgov-nct03323476-2026-03-20`, retrieved 2026-10-26)
- Countries: France (ClinicalTrials.gov record NCT03323476, source copy `cardio:ctgov-nct03323476-2026-03-20`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03323476-2026-03-20`, retrieved 2026-10-26)

## The registry's words

- Brief title: Maintaining or Stopping Immunosuppressive Therapy in Patients With ANCA Vasculitis and End-stage Renal Disease
- Acronym: MASTER-ANCA
- Condition: Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
- Condition: End Stage Renal Disease
- Intervention (Other): Discontinuation (or not initiation) of Immunosuppressive Therapy
- Intervention (Drug): Maintenance (or initiation) of immunosuppressive treatment: Imurel®, Mabthera®,Cellcept®, Cortancyl®
- Lead sponsor: Centre Hospitalier Departemental Vendee
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry lists this organization as the lead sponsor: Centre Hospitalier Departemental Vendee (`cardio:org-centre-hospitalier-departemental-vendee`)

## Provenance

Content hash: af9deb92626d29a21ead4744549c28263c97d7199c6156fb4c7da52e3edddc47
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
